Clinical characteristics and outcomes for patients with ME
| No. . | Age . | Sex . | ME site . | M protein type . | ISS . | FISH . | Time between diagnosis and ME (mo) . | Other EMD . | Type of therapy after ME . | Survival time (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|
| MM01 | 59 | F | Pleural | IgG-κ | III | amp(1q21) t(4;14) del(17p) | 1 | Chest wall lesions | Dara + BD | 4 (2)∗ |
| MM02 | 64 | M | Pleural | IgG-κ | III | amp(1q21) t(4;14) | 27 | NA | BPD | 27 (1)∗ |
| MM03 | 56 | M | Peritoneal | IgA-κ | III | None | 24 | Liver lesion | DCEP and PAD | 32 (8)∗ |
| No. . | Age . | Sex . | ME site . | M protein type . | ISS . | FISH . | Time between diagnosis and ME (mo) . | Other EMD . | Type of therapy after ME . | Survival time (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|
| MM01 | 59 | F | Pleural | IgG-κ | III | amp(1q21) t(4;14) del(17p) | 1 | Chest wall lesions | Dara + BD | 4 (2)∗ |
| MM02 | 64 | M | Pleural | IgG-κ | III | amp(1q21) t(4;14) | 27 | NA | BPD | 27 (1)∗ |
| MM03 | 56 | M | Peritoneal | IgA-κ | III | None | 24 | Liver lesion | DCEP and PAD | 32 (8)∗ |
BPD, bortezomib/pomalidomide/dexamethasone; Dara + BD, daratumumab/bortezomib/dexamethasone; DCEP, dexamethasone/cyclophosphamide/etoposide/cisplatin; EMD, extramedullary disease; Ig, immunoglobulin; F, female; FISH, fluorescence in situ hybridization; ISS, International Staging System; M, male; PAD, pomalidomide/doxorubicin/dexamethasone.
For survival time in parentheses, from the diagnosis of ME to death.